Updates are available Correction dated 2024-06-07

Article History

Received: 5 July 2023

Accepted: 19 September 2023

First Online: 5 October 2023

Change Date: 7 June 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40744-024-00679-w

Declarations

:

: Agner R. Parra Sánchez has received grant/research support (institutional grants) from AstraZeneca; received support for attending meetings and/or travel from Amsterdam UMC. The work of ARPS is supported by the European Union’s Horizon 2020 research and innovation program (“ARCAID”; ; grant agreement nr. 847551). Ronald F. van Vollenhoven has received grant/research support from Bristol Myers Squibb (BMS) and UCB; received support for educational programs from AstraZeneca, Galapagos, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB; received consulting fees from AbbVie, AstraZeneca, Biogen, BMS, Galapagos, Janssen, Pfizer, and UCB; and received speaking fees and/or honoraria from AbbVie, AstraZeneca, BMS, Galapagos, GlaxoSmithKline (GSK), Janssen, Pfizer, and UCB. Eric F. Morand has received grant support from AbbVie, Amgen, AstraZeneca, Biogen, BMS, Eli Lilly and Company, EMD Serono, Genentech, GSK, Janssen, and UCB Pharma; received consulting fees from AbbVie, Amgen, AstraZeneca, Biogen, BMS, Eli Lilly and Company, EMD Serono, Genentech, GSK, Janssen, Novartis, Servier, Wolf, and Zenas; received speaking fees and/or honoraria from AstraZeneca, Biogen, BMS, EMD Serono, and Gilead; received support for attending meetings and/or travel from AstraZeneca; and served in a leadership or fiduciary role as Board Director at Rare Voices Australia. Ian N. Bruce is a National Institute for Health Research (NIHR) Senior Investigator and is funded by the NIHR Manchester Biomedical Research Centre (NIHR 203308). His institution has received research grants from GSK and Genzyme/Sanofi and consultancy fees from GSK, UCB, Eli Lilly, BMS, Merck Serono, Aurinia and IL-TOO. Dr Bruce has received speaker fees from GSK, AstraZeneca and UCB; he also participated on a Data Safety Monitoring Board or Advisory Board for AstraZeneca and Merck Serono. Rangi Kandane-Rathnayake declares that there is no conflict of interest. Gudrun Weiss, Raj Tummala, and Hussein Al-Mossawi are all employees of and may hold stock in AstraZeneca. Alessandro Sorrentino is an employee of AstraZeneca and holds stock in Abbott, Galapagos, Gilead, and Moderna.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.